GPX4 and cancer: Their results suggested that the ferroptosis sensibility can be predicted by the NAD(P)H and CoQ levels and that combining GPx4 inhibitors with FSP1 inhibitors might be a better cocktail for ferroptosis induction in therapy-resistant cancer cells [180].